Emibetuzumab
Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | HGFR |
| Clinical data | |
| Other names | LY2875358 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6356H9810N1694O2014S48 |
| Molar mass | 143.7 kg/mol g·mol−1 |
This drug was developed by Eli Lilly & Company.
References
- World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.
- http://meetinglibrary.asco.org/content/164953-176
Growth factor receptor modulators | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angiopoietin |
| ||||||||||
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| |||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.